Intech Investment Management LLC Buys 8,206 Shares of McKesson Corporation $MCK

Intech Investment Management LLC grew its position in shares of McKesson Corporation (NYSE:MCK) by 28.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,750 shares of the company’s stock after purchasing an additional 8,206 shares during the period. Intech Investment Management LLC’s holdings in McKesson were worth $28,391,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Catalyst Financial Partners LLC boosted its stake in McKesson by 2.6% during the third quarter. Catalyst Financial Partners LLC now owns 969 shares of the company’s stock valued at $749,000 after buying an additional 25 shares during the last quarter. Hager Investment Management Services LLC increased its stake in McKesson by 2.6% in the 3rd quarter. Hager Investment Management Services LLC now owns 1,332 shares of the company’s stock worth $1,029,000 after acquiring an additional 34 shares during the last quarter. Empirical Asset Management LLC purchased a new stake in shares of McKesson during the 3rd quarter worth approximately $205,000. GGM Financials LLC bought a new position in shares of McKesson during the 3rd quarter valued at approximately $25,000. Finally, Cary Street Partners Financial LLC boosted its position in shares of McKesson by 10.1% during the 3rd quarter. Cary Street Partners Financial LLC now owns 186 shares of the company’s stock valued at $144,000 after acquiring an additional 17 shares during the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MCK shares. Morgan Stanley restated an “overweight” rating and issued a $966.00 price target on shares of McKesson in a research report on Thursday, January 29th. Zacks Research cut shares of McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Weiss Ratings downgraded shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. UBS Group upped their target price on shares of McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Evercore reiterated an “outperform” rating and issued a $1,000.00 price target on shares of McKesson in a research report on Thursday, November 6th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, McKesson has an average rating of “Moderate Buy” and an average price target of $943.50.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Large institutional inflows are cited as a key driver behind the stock’s rally, suggesting continued demand from “big money” managers supporting higher valuations. Read More.
• Positive Sentiment: Barclays raised its price target to $1,050 (from $960) and kept an Overweight rating, signaling analyst conviction that shares should remain in favor — this helps push buyers toward the stock. Read More.
• Positive Sentiment: Recent quarterly results beat estimates and McKesson set FY2026 EPS guidance (38.80–39.20), which underpins the bullish analyst revisions and investor inflows. Read More.
• Neutral Sentiment: Industry research lists McKesson among vendors in an expanding Radiology Information Systems market — a longer-term market opportunity but not an immediate stock catalyst. Read More.
• Neutral Sentiment: Brokerage coverage remains skewed to Buy/Outperform (consensus “Moderate Buy”), which supports sentiment but leaves limited immediate upside unless fundamentals surprise further. Read More.
• Negative Sentiment: Faruqi & Faruqi launched a review of McKesson’s proposed share issuance and board conduct, raising governance and dilution concerns that could pressure the stock if the issuance proceeds or litigation follows. Read More.
• Negative Sentiment: An exec director sold ~349 shares (~$328k), a disclosed insider sale that investors may view as minor profit-taking but still worth noting amid governance scrutiny. Read More.
• Negative Sentiment: Some analysts/commentaries (e.g., Seeking Alpha) argue upside could be limited from current levels despite strong results, suggesting some investors may be taking profits. Read More.

Insiders Place Their Bets

In other news, Director Maria Martinez sold 349 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the sale, the director directly owned 301 shares of the company’s stock, valued at approximately $282,900.87. The trade was a 53.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,143 shares of company stock worth $1,046,070 in the last 90 days. 0.08% of the stock is owned by insiders.

McKesson Trading Up 0.6%

MCK stock opened at $962.65 on Thursday. McKesson Corporation has a 12 month low of $619.48 and a 12 month high of $971.93. The company has a 50-day moving average price of $862.22 and a 200 day moving average price of $802.17. The stock has a market cap of $117.91 billion, a PE ratio of 27.69, a P/E/G ratio of 1.54 and a beta of 0.40.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same period in the prior year, the company posted $8.03 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts forecast that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.